Top

Pediatric Drugs

Published in:

01-12-2009 | Review Article

Juvenile Dermatomyositis

Advances in Pathogenesis, Evaluation, and Treatment

Author: Dr Adam M. Huber

Published in: Pediatric Drugs | Issue 6/2009

Abstract

Juvenile dermatomyositis (JDM) is a rare, presumably autoimmune illness that causes proximal muscle weakness and a variety of typical cutaneous features. The study of this illness has been hampered by its rarity but, in recent years, important developments have increased our understanding of JDM. Genetic factors are likely important in the pathogenesis of JDM. These include several Human Leukocyte Antigen alleles, in particular those associated with the 8.1 ancestral haplotype and the tumor necrosis factor-α gene 308 polymorphism. Microchimerism, activation of plasmacytoid dendritic cells, and upregulation of type-1 interferon inducible genes also appear to play an important role in the pathogenesis of JDM.

The study of JDM has also been limited by a lack of validated assessment tools. Recent work has validated the Childhood Myositis Assessment Scale and the Childhood Health Assessment Questionnaire as measures of muscle strength and function, and the Cutaneous Assessment Tool as a measure of skin disease activity and damage. Development of core sets of tools that should be used in all JDM studies has also been an important step. The use of magnetic resonance imaging and novel laboratory assessments (such as type-1 interferon inducible gene products, peripheral blood B cell and natural killer cell numbers, and myositis-associated and myositis-specific autoantibodies) are also playing an increasing role in the diagnosis and assessment of JDM.

Current treatment is with corticosteroids, frequently in combination with other medications such as methotrexate or intravenous gammaglobulin. Newer therapies, such as anti-tumor necrosis factor agents and rituximab are currently being evaluated; it is not clear what role these medications will have in the future.

Mendez EP, Lipton R, Ramsey-Goldman R, et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49(3): 300–5PubMedCrossRef

Feldman BM, Rider LG, Reed AM, et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371: 2201–12PubMedCrossRef

Pachman LM. Juvenile dermatomyositis: pathophysiology and disease expression. Pediatr Clin North Am 1995; 42(5): 1071–98PubMed

Wedderburn L, McHugh N, Chinoy H, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology 2007; 46:1786–9PubMedCrossRef

Candore G, Lio D, Colanna Romano G, et al. Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev 2002; 1(1–2): 29–35PubMedCrossRef

Mamyrova G, O’Hanlon T, Monroe J, et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 2006; 54(12): 3979–87PubMedCrossRef

O’Hanlon T, Rider LG, Mamyrova G, et al. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy. Arthritis Rheum 2006; 54(11): 3670–81PubMedCrossRef

Tomono N, Mori M, Nakajima S, et al. HLA-DRBl*15021 is the predominant allele in Japanese patients with juvenile dermatomyositis. J Rheumatol 2004; 31(9): 1847–50PubMed

Pachman LM, Liotta-Davis M, Hong D, et al. TNFa-308A allele in juvenile dermatomyositis-association with increased TNF-alpha production, disease duration, and pathologic calcifications. Arthritis Rheum 2000; 43: 2368–77PubMedCrossRef

10.

Pachman LM, Fedczyna T, Lutz J, et al. Juvenile dermatomyositis: the association of the TNFa-308 allele and disease chronicity. Curr Opin Rheumatol 2001; 5: 379–86

11.

Pachman LM, Lingen M, Caliendo J, et al. Muscle biopsy findings in 38 untreated children with juvenile dermatomyositis (JDM): capillary occlusion is associated with the TNF-alpha allele [abstract]. Arthritis Rheum 1999; 42 Suppl.: S403

12.

Lutz J, Huwiler K, Fedczyna T, et al. Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis. Clin Immunol 2002; 103: 260–3PubMedCrossRef

13.

Chinoy H, Salway F, John S, et al. Tumour necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. Rheumatology 2007; 46:1411–6PubMedCrossRef

14.

Hassan A, Nikitina-Zake L, Sanjeevi C, et al. Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositis. Arthritis Rheum 2004; 50(3): 1013–5PubMedCrossRef

15.

Reed AM. Microchimerism in children with rheumatic disease: what does it mean? Curr Rheumatol Rep 2003; 5: 458–62PubMedCrossRef

16.

Reed AM, Shock L, Picornell Y. Chimerism in JDM [abstract]. Arthritis Rheum 1999; 41 Suppl.: S362

17.

Artlett C, Miller FW, Rider LG. Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. Rheumatology 2001; 40(11): 1279–84PubMedCrossRef

18.

Artlett C, Ramos R, Jiminez S, et al. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. Lancet 2000; 356(9248): 2155–6PubMedCrossRef

19.

McNallan K, Reed AM. Immunophenotyping of chimeric cells in juvenile dermatomyositis [abstract]. Arthritis Rheum 2003; 48(9 Suppl.): S104

20.

Reed AM, Picornell Y, Harwood A, et al. Chimerism in children with juvenile dermatomyositis. Lancet 2000; 356: 2156–7PubMedCrossRef

21.

Reed AM, McNallan K, Wettstein P, et al. Does HLA-dependant chimerism underlie the pathogenesis of juvenile dermatomyositis? J Immunol 2004; 172: 5041–6PubMed

22.

Bakay M, Wang Z, Melcon G, et al. Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain 2006; 129: 996–1013PubMedCrossRef

23.

Tezak Z, Hoffman E, Lutz J, et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002; 168(8): 4154–63PubMed

24.

Greenberg S, Pinkus J, Pinkus G, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57(5): 664–78PubMedCrossRef

25.

Fall N, Bove K, Stringer K, et al. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis. Arthritis Rheum 2005; 52(10): 3175–80PubMedCrossRef

26.

Christen-Zaech S, Seshadri R, Sundberg J, et al. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58(2): 571–6PubMedCrossRef

27.

Griffin TA, Reed AM. Pathogenesis of myositis in children. Curr Opin Rheumatol 2007; 19: 489–91CrossRef

28.

O’Connor K, Abbott K, Sabin B, et al. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 2006; 120: 319–25PubMedCrossRef

29.

Baechler E, Bauer J, Slattery C, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007; 13(1–2): 59–68PubMed

30.

Chinoy H, Salway F, John S, et al. Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in the UK. Ann Rheum Dis 2007; 66: 970–3PubMedCrossRef

31.

Page G, Chevrel G, Moissec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum 2004; 50: 199–208PubMedCrossRef

32.

Nagaraju K, Rider LG, Fan C, et al. Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis 2006; 20(3): 2CrossRef

33.

Lopez de Padilla C, Vallejo A, McNallan K, et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007; 56(5): 1658–68PubMedCrossRef

34.

Pachman LM. Juvenile dermatomyositis: immunogenetics, pathophysiology, and disease expression. Rheum Dis Clin North Am 2002; 28: 579–602PubMedCrossRef

35.

Mamyrova G, Rider LG. Parvovirus B19 and onset of juvenile dermatomyositis. JAMA 2005; 294(17): 2170–1PubMedCrossRef

36.

Pachman LM, Hayford J, Hochberg M, et al. New-onset juvenile dermatomyositis: comparisons with a healthy cohort and children the juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40(8): 1526–33PubMedCrossRef

37.

Pachman LM, Lipton R, Ramsey-Goldman R, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 2005; 53(2): 166–72PubMedCrossRef

38.

Vegosen L, Weinberg C, O’Hanlon T, et al. Seasonal birth patterns in myositis subgroups suggest an etiologic role for early environmental exposures. Arthritis Rheum 2007; 56(8): 2719–28PubMedCrossRef

39.

Massa M, Costouros N, Mazzoli F, et al. Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum 2002; 46(11): 3015–25PubMedCrossRef

40.

Elst E, Klein M, de Jager W, et al. Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58(2): 547–55PubMedCrossRef

41.

Medical Research Council. War memorandum no. 7. Aids to the investigation of peripheral nerve injuries. London: H.M. Stationery Office, 1942

42.

Jain M, Smith M, Cintas H, et al. Intra-rater and inter-rater reliability of the 10-point manual muscle test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). Phys Occup Ther Pediatr 2006; 26(3): 5–17PubMedCrossRef

43.

Lovell DJ, Lindsley CB, Rennebohm RM, et al. Development of disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999; 42(10): 2213–9PubMedCrossRef

44.

Huber AM, Feldman BM, Rennebohm RM, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale (CMAS) for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004; 50(5): 1595–603PubMedCrossRef

45.

Singh G, Athreya BH, Fries JF, et al. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37(12): 1761–9PubMedCrossRef

46.

Feldman BM, Ayling-Campos A, Luy L, et al. Measuring disability in juvenile dermatomyositis. Validity of the Childhood Health Assessment Questionnaire. J Rheumatol 1995; 22(2): 326–31PubMed

47.

Huber AM, Hicks JE, Lachenbruch PA, et al. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic inflammatory myopathies. J Rheumatol 2001; 28(5): 1106–11PubMed

48.

Huber AM, Dugan EM, Lachenbruch PA, et al. The Cutaneous Assessment Tool (CAT): development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology 2007; 46(10): 1606–11PubMedCrossRef

49.

Huber AM, Dugan EM, Lachenbruch PA, et al. Preliminary validation and clinical meaning of the cutaneous assessment tool (CAT) in juvenile dermatomyositis. Arthritis Rheum 2008; 59(2): 214–21PubMedCrossRef

50.

Huber AM, Lachenbruch PA, Dugan EM, et al. Alternative scoring of the Cutaneous Assessment Tool (CAT) in juvenile dermatomyositis: results using an abbreviated format. Arthritis Rheum 2008; 59(3): 352–6PubMedCrossRef

51.

Carroll CL, Lang W, Snively B, et al. Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol 2008; 158(2): 345–50PubMedCrossRef

52.

Klein R, Bangert C, Costner M, et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008 Sep; 159(4): 887–94PubMedCrossRef

53.

Maricq H, Blume R, LeRoy E. Wide-field study of nailfold capillary bed in disorders of connective tissue. In: 6th European Conference on Microcirculation; 1970 Jun 22–26; Aalborg. Basel: Karger, 1971: 116–22

54.

Smith R, Sundberg J, Shamiyah E, et al. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 2004; 31(8): 1644–9PubMed

55.

Nascif A, Terreri M, Len C, et al. Inflammatory myopathies in childhood: correlation between nailfold capillaroscopy findings and clinical and laboratory data. J Pediatr (Rio J) 2006; 82(1): 40–5CrossRef

56.

Punaro L, Stichweh D, Powell M, et al. Aspiration: hidden risk for patients with juvenile dermatomyositis [abstract]. Clin Exp Rheumatol 2004; 22 Suppl.: S104

57.

McCann L, Garay S, Ryan M, et al. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology 2007; 46: 1363–6PubMedCrossRef

58.

Rider LG, Feldman BM, Perez MD, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies I: physician, parent and patient global assessments. Arthritis Rheum 1997; 40(11): 1976–83PubMedCrossRef

59.

Bode RK, Klein-Gitelman MS, Miller ML, et al. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Care Res 2003; 49(1): 7–15CrossRef

60.

Ruperto N, Ravelli A, Pistorio A, et al. The provisional Pediatric Rheumatology International Trials Organization/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008; 59(1): 4–13PubMedCrossRef

61.

Miller FM, Rider LG, Chung Y, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathy. Rheumatology 2001; 40: 1262–73PubMedCrossRef

62.

Ruperto N, Ravelli A, Murray K, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 2003; 42(12): 1452–9PubMedCrossRef

63.

Rider LG, Giannini EH, Brunner HI, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50(7): 2281–90PubMedCrossRef

64.

Maillard S, Jones R, Owens C, et al. Quantitative assessment of MRI T2 relaxation time in thigh muscles in juvenile dermatomyositis. Rheumatology 2004; 43: 603–8PubMedCrossRef

65.

Kimball AB, Summers RM, Turner M, et al. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis: implications for diagnosis and therapy. Arthritis Rheum 2000; 43(8): 1866–73PubMedCrossRef

66.

Summers RM, Brune AM, Choyke PL, et al. Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery imaging. Radiology 1998; 209(1): 191–6PubMed

67.

Brown V, Pilkington C, Feldman BM, et al. An international consensus survey on the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxf) 2006; 45: 990–3CrossRef

68.

De Benedetti F, De Amici M, Aramini L, et al. Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. Arch Dis Child 1993; 69(2): 232–5PubMedCrossRef

69.

Rider LG, Schiffenbauer A, Zito M, et al. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin Chem 2002; 48(10): 1681–8PubMed

70.

Eisenstein D, O’Gorman M, Pachman LM. Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis. J Rheumatol 1997; 24(9): 1830–2PubMed

71.

O’Gorman M, Bianchi L, Zaas D, et al. Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis. Clin Diagn Lab Immunol 2000; 7(4): 693–7PubMed

72.

Mizuno K, Yachie A, Nagaoki S, et al. Oligoclonal expansion of circulating and tissue-infiltrating CD8+ T cells with killer/effector phenotypes in juvenile dermatomyositis syndrome. Clin Exp Immunol 2004; 137: 187–94PubMedCrossRef

73.

Targoff I. Myositis specific antibodies. Curr Rheumatol Rep 2006; 8(3):196–203PubMedCrossRef

74.

Mimori T, Imura Y, Nakashima R, et al. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007; 19: 523–9PubMedCrossRef

75.

Targoff I, Mamyrova G, Trieu E, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54(11): 3682–9PubMedCrossRef

76.

Feldman BM, Reichlin M, Laxer RM, et al. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 1996; 23(10): 1794–7PubMed

77.

Rider LG, Miller FW, Targoff I, et al. A broadened spectrum of juvenile myositis: myositis-specific autoantibodies in children. Arthritis Rheum 1994; 37(10): 1534–8PubMedCrossRef

78.

Gunawardena H, Wedderburn L, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology 2008; 47(3): 324–8PubMedCrossRef

79.

Li C, Hemlata V, Holton J, et al. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 2004; 31(3): 605–9PubMed

80.

McCann L, Li C, Varsani H, et al. Failure to over express MHC Class I on muscle biopsy in a case of amyopathic juvenile dermatomyositis. Clin Exp Rheumatol 2007; 25(1): 96–8PubMed

81.

Miles L, Bove K, Lovell DJ, et al. Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum 2007; 57(7): 1183–91PubMedCrossRef

82.

Wedderburn L, Varsani H, Li C, et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 2007; 57(7): 1192–201PubMedCrossRef

83.

Miller ML, Smith R, Abbott K, et al. Use of etanecept in chronic juvenile dermatomyositis (JDM) [abstract]. Arthritis Rheum 2002; 46 Suppl.: S306

84.

Miller ML, Mendez EP, Klein-Gitelman MS, et al. Experience with etanercept in chronic juvenile dermatomyositis (JDM): preliminary results [abstract]. Arthritis Rheum 2000; 43 Suppl.: S380CrossRef

85.

Stringer E, Feldman BM. Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol 2006; 18: 503–6PubMedCrossRef

86.

Riley P, McCann L, Maillard S, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 2008; 47(6): 877–80PubMedCrossRef

87.

Levine T. A pilot study of rituximab therapy for refractory dermatomyositis [abstract]. Arthritis Rheum 2002; 46 Suppl.: S488

88.

Endo L, Theos A, Atkinson T. Use of rituximab in refractory juvenile dermatomyositis [abstract]. Arthritis Rheum 2005; 52 Suppl.: S288

89.

Cooper M, Willingham D, Brown D, et al. Rituximab for the treatment of juvenile dermatomyositis: a report of 4 pediatric cases. Arthritis Rheum 2007; 56(9): 3107–11PubMedCrossRef

90.

Dinh H, McCormack C, Hall S, et al. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007; 56(1): 148–53PubMedCrossRef

91.

Fisler RE, Liang MG, Fuhlbrigge RC, et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002; 47: 505–11PubMedCrossRef

92.

Ramanan A, Campbell-Webster N, Ota S, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005; 52(11): 3570–8PubMedCrossRef

93.

Riley P, Maillard S, Wedderburn L, et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis: a review of efficacy and safety. Rheumatology 2004; 43: 491–6PubMedCrossRef

94.

Yamada A, Ohshima Y, Omata N, et al. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting with poor bioavailability of cyclosporine A. Eur J Pediatr 2004; 163(9): 561–2PubMedCrossRef

95.

Martin Nalda A, Modesto Caballero C, Arnal Guimeral C, et al. Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases [in Spanish]. Med Clin (Barc) 2006; 127(18): 697–701CrossRef

96.

Garcia-Doval I, Cruces M. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients. Dermatology 2004; 209(3): 247–8PubMedCrossRef

97.

Hollar C, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatol Treat 2004; 15(1): 35–9CrossRef

Title: Juvenile Dermatomyositis
Advances in Pathogenesis, Evaluation, and Treatment
Author: Dr Adam M. Huber
Publication date: 01-12-2009
Publisher: Springer International Publishing
Published in: Pediatric Drugs / Issue 6/2009
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI: https://doi.org/10.2165/11310550-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Juvenile Dermatomyositis

Advances in Pathogenesis, Evaluation, and Treatment

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2009

Vasculitis in Children and Adolescents

Acknowledgment

Topical Pimecrolimus

Treatment Strategies to Minimize or Prevent Chronic Allograft Dysfunction in Pediatric Renal Transplant Recipients

Pediatric Safety of Tizanidine